Tirzepatide Treatment and Associated Changes in β-Cell Function and Insulin Sensitivity in People With Obesity or Overweight With Prediabetes or Normoglycemia: A Post Hoc Analysis From the SURMOUNT-1 Trial [0.03%]
司美格鲁肽治疗对肥胖或超重且有前驱糖尿病或血糖正常人群的β细胞功能和胰岛素敏感性的影响：来自SURMOUNT-1试验的事后分析
Andrea Mari,Adam Stefanski,Daniel H van Raalte et al.
Andrea Mari et al.
Objective: We assessed insulin sensitivity and β-cell function in adults with obesity/overweight, without diabetes, treated with tirzepatide for 72 weeks. ...
Identifying Type 2 Diabetes Risk at Birth: A New Frontier for Early Prevention [0.03%]
出生即识别2型糖尿病风险：早期防治的新前沿
Gernot Desoye,David Simmons,Mireille van Poppel
Gernot Desoye
Moving the Goalposts Closer: Using Intermediate End Points in Type 1 Diabetes Prevention Trials [0.03%]
让目标更易达成：1型糖尿病预防试验中使用中间临床终点
Guy I Sydney,Samuel S Wu,Kevan C Herold
Guy I Sydney
Do Extracellular Vesicles Mediate the Muscle Insulin Resistance of Obesity and Type 2 Diabetes? [0.03%]
胞外囊泡介导肥胖和2型糖尿病肌糖原累积及肌糖耐量异常的作用机制研究？
Kelli A Lytle,Michael D Jensen
Kelli A Lytle
The Ongoing Need to Address Cost-Related Nonadherence to Diabetes Medications [0.03%]
应对糖尿病药物相关费用的长期需求以提高患者依从性
Anna Hung,Caroline E Sloan
Anna Hung
About the Editor: Sonia Angell, MD, MPH-Evidence for Policy and Systems Change [0.03%]
关于执行编辑Sonia Angell,MD,MPH：为政策和系统变革提供证据
Benjamin Page
Benjamin Page
Editorial
Diabetes care. 2025 Aug 1;48(8):1298. DOI:10.2337/dci25-0073 2025
Benjamin Page
Benjamin Page
Editorial
Diabetes care. 2025 Aug 1;48(8):1297. DOI:10.2337/dci25-0072 2025
Response to Comment on Pradhan et al. Glucagon-Like Peptide 1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors and the Prevention of Cirrhosis Among Patients With Type 2 Diabetes. Diabetes Care 2025;48:444-454 [0.03%]
对Pradhan等关于GLP-1受体激动剂和SGLT-2抑制剂预防2型糖尿病患者肝硬化的评论的回复：Diabetes Care 2025;48:444-454
Richeek Pradhan,Laurent Azoulay
Richeek Pradhan
Comment on Pradhan et al. Glucagon-Like Peptide 1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors and the Prevention of Cirrhosis Among Patients With Type 2 Diabetes. Diabetes Care 2025;48:444-454 [0.03%]
Pradhan等关于GLP-1受体激动剂和SGLT2抑制剂在预防2型糖尿病患者肝硬化方面的评论。Diabetes Care 2025;48:444-454
Edy Kornelius
Edy Kornelius